The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
WB: Use at a concentration of 1 - 2 µg/ml. Predicted molecular weight: 18 kDa.
It is recommended that ab90878 be used under reducing conditions only.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Ligand for IL17RA and IL17RC (PubMed:17911633). The heterodimer formed by IL17A and IL17F is a ligand for the heterodimeric complex formed by IL17RA and IL17RC (PubMed:18684971). Involved in stimulating the production of other cytokines such as IL6, IL8 and CSF2, and in regulation of cartilage matrix turnover (PubMed:11591732, PubMed:11591768, PubMed:11574464). Also involved in stimulating the proliferation of peripheral blood mononuclear cells and T-cells and in inhibition of angiogenesis (PubMed:11591732). Plays a role in the induction of neutrophilia in the lungs and in the exacerbation of antigen-induced pulmonary allergic inflammation.
Expressed in activated, but not resting, CD4+ T-cells and activated monocytes.
Western blot - IL17F antibody [H17F10A7] (ab90878)
All lanes : Anti-IL17F antibody [H17F10A7] (ab90878) at 2 µg/ml
Lane 1 : IL17 producing cells treated with Brefeldin A for 16 hours Lane 2 : IL17 producing cells treated with PMA and Ionomycin in the presence of Brefeldin A for 16 hours
Secondary All lanes : anti-mouse HRP conjugated polyclonal antibody.
Performed under reducing conditions.
Predicted band size: 18 kDa
IL17 producing cells were generated by culturing Human PBMC with anti-CD3 and anti-CD28 in the presence of recombinant Human IL23 for 3 days, followed by 3 days with IL-23 alone. Day 6 cultures were then treated as above.